Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US7033582B2 · kind B2 · utility
49Cited by
31References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2004 |
| Grant date | Apr 25, 2006 |
| Priority date | — |
| Expiry date | Aug 17, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/785
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention involves the administration of Copolymer 1 (glatiramer acetate) to treat inflammatory, non-autoimmune central nervous system (CNS) diseases, alleviate the symptoms thereof, inhibit the activity of matrix metalloproteinases and suppress cytokine production by T lymphocytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.